Menu Search
Equities

Procept Biorobotics Corp

PRCT:NMQ

Procept Biorobotics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)99.07
  • Today's Change2.84 / 2.95%
  • Shares traded742.53k
  • 1 Year change+201.49%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy3
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Procept Biorobotics Corp have a median target of 103.50, with a high estimate of 110.00 and a low estimate of 99.00. The median estimate represents a 4.47% increase from the last price of 99.07.
High11.0%110.00
Med4.5%103.50
Low-0.1%99.00

Earnings history & estimates in USD

On Oct 28, 2024, Procept Biorobotics Corp reported 3rd quarter 2024 losses of -0.40 per share. This result exceeded the -0.49 consensus loss of the 7 analysts covering the company and exceeded last year's 3rd quarter results by 21.57%.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate+5.41%
Procept Biorobotics Corp reported annual 2023 losses of -2.24 per share on Feb 27, 2024.
Average growth rate+15.86%
More ▼

Revenue history & estimates in USD

Procept Biorobotics Corp had 3rd quarter 2024 revenues of 58.37m. This bettered the 53.18m consensus of the 8 analysts covering the company. This was 139.18% above the prior year's 3rd quarter results.
Average growth rate+13.89%
Procept Biorobotics Corp had revenues for the full year 2023 of 136.19m. This was 81.55% above the prior year's results.
Average growth rate+99.58%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.